References

1. Dewick, P.M. Medicinal Natural Products: A Biosynthetic Approach, 3rd ed.; Wiley & Sons: Chichester, UK, 2009.
2. Gao, W.; Bohl, C.E.; Dalton, J.T. Chemistry and structural biology of androgen receptor. Chem. Rev. 2005, 105, 3352–3370.
3. Peterson, M.D.; Belakovskiy, A.; McGrath, R.; Yarrow, J.F. Testosterone deficiency, weakness, and multimorbidity in men. Sci. Rep. 2018, 8.
4. Barceloux, D.G.; Palmer, R.B. Anabolic-androgenic steroids. Dis. Mon. 2013, 59, 226–248.
5. Parkinson, A.B.; Evans, N.A. Anabolic androgenic steroids: A survey of 500 users. Med. Sci. Sports Exerc. 2006, 38, 644–651.
6. de Ronde, W.; Smit, D.L. Anabolic androgenic steroid abuse in young males. Endocr. Connect. 2020, 9, R102–R111.
7. Ullah, M.I.; Riche, D.M.; Koch, C.A. Transdermal testosterone replacement therapy in men. Drug Des. Devel. Ther. 2014, 8, 101–112.
8. Efros, M.; Carrara, D.; Neijber, A. The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: Results from phase ii open-label studies. Andrologia 2016, 48, 637–645.
9. Dinsmore, W.W.; Wyllie, M.G. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. BJU Int. 2012, 110, 162–169.
10. Bloemers, J.; van Rooij, K.; de Leede, L.; Frijlink, H.W.; Koppeschaar, H.P.F.; Olivier, B.; Tuiten, A. Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: A pharmacokinetic comparison. Br. J. Clin. Pharmacol. 2016, 81, 1091–1102.
11. Banks, W.A.; Morley, J.E.; Niehoff, M.L.; Mattern, C. Delivery of testosterone to the brain by intranasal administration: Comparison to intravenous testosterone. J. Drug Target. 2009, 17, 91–97.
12. Saad, F.; Caliber, M.; Doros, G.; Haider, K.S.; Haider, A. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. Aging Male 2020, 23, 81–92.
13. Lobo, R.A. Androgens in postmenopausal women: Production, possible role, and replacement options. Obstet. Gynecol. Surv. 2001, 56, 361–376.
14. Ruzicka, L.; Goldberg, M.W.; Rosenberg, H.R. Sexualhormone x. herstellung des 17-methyl-testosterons und anderer androsten- und androstanderivate. zusammenhänge zwischen chemischer konstitution und männlicher hormonwirkung. Helv. Chim. Acta 1935, 18, 1487–1498.
15. Laschet, U.; Laschet, L.; Paarmann, H.F. Gonadotropin and steroid hormone excretion during treatment with 1-alpha-methyl-5-alpha-androstan-17-beta-ol-3-one (mesterolone). Arzneim.-ForschungDrug Res. 1966, 16, 469–471.
16. Corona, G.; Rastrelli, G.; Vignozzi, L.; Maggi, M. Emerging medication for the treatment of male hypogonadism. Expert Opin. Emerg. Drugs 2012, 17, 239–259.
17. Yoshihiko, S.; Shigeo, B. Stable isotope methodology in the pharmacokinetic studies of androgenic steroids in humans. Steroids 1990, 55, 170–176.
18. Kicman, A.T. Pharmacology of anabolic steroids. Br. J. Pharmacol. 2008, 154, 502–521.
19. Kasdon, S.C.; Fishman, W.H.; Dart, R.M.; Bonner, C.D.; Homburger, F. Methylandrostenediol in palliative treatment of breast cancer. J. Am. Med. Assoc. 1952, 148, 1212–1216.
20. Homburger, F.; Kasdon, S.C.; Fishman, W.H. Methylandrostenediol: A non-virilizing derivative of testosterone in metastatic cancer of the breast. Proc. Soc. Exp. Biol. Med. 1950, 74, 162–164.
21. Holma, P.K. Effects of an anabolic steroid (metandienone) on spermatogenesis. Contraception 1977, 15, 151–162.
22. Basaria, S.; Wahlstrom, J.T.; Dobs, A.S. Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J. Clin. Endocrinol. Metab. 2001, 86, 5108–5117.
23. Strickland, A.L. Long-term results of treatment with low-dose fluoxymesterone in constitutional delay of growth and puberty and in genetic short stature. Pediatrics 1993, 91, 716–720.
24. Ingle, J.N. Additive hormonal therapy in women with advanced breast cancer. Cancer 1984, 53, 766–777.
25. Lo, T.E.N.; Andal, Z.C.; Lantion-Ang, F.L. Fluoxymesterone-induced gynaecomastia in a patient with childhood aplastic anaemia. BMJ Case Rep. 2015, 2015, bcr2014207474.
26. Fürstenberger, C.; Vuorinen, A.; Da Cunha, T.; Kratschmar, D.V.; Saugy, M.; Schuster, D.; Odermatt, A. The anabolic androgenic steroid fluoxymesterone inhibits 11β-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation. Toxicol. Sci. 2012, 126, 353–361.
27. Bennett, M.B.; Helman, P.; Palmer, P. Hormonal therapy of breast cancer with special reference to masteril therapy. S. Afr. Med. J. 1975, 49, 2036–2040.
28. Krug, K. Contribution to the pathophysiology of the aplastic anaemia and its treatment with metenolone enanthate. Z. Gesamte Inn. Med. 1980, 35, 809–812.
29. Orr, R.; Fiatarone Singh, M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: Review of efficacy and safety. Drugs 2004, 64, 725–750.
30. Church, J.A. Oxandrolone treatment of childhood hereditary angioedema. Ann. Allergy. Asthma. Immunol. 2004, 92, 377–378.
31. Reeves, P.T.; Herndon, D.N.; Tanksley, J.D.; Jennings, K.; Klein, G.L.; Mlcak, R.P.; Clayton, R.P.; Crites, N.N.; Hays, J.P.; Andersen, C.; et al. Five-year outcomes after long-term oxandrolone administration in severely burned children: A randomized clinical trial. Shock Augusta Ga 2016, 45, 367–374.
32. Rosenfeld, R.G.; France, J.; Attie, K.M.; Brasel, J.A.; Burstein, S.; Cara, J.F.; Chernausek, S.; Gotlin, R.W.; Kuntze, J.; Lippe, B.M.; et al. Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in turner syndrome. J. Pediatr. 1992, 121, 49–55.
33. Keele, D.K.; Vose, G.P. A study of bone density: Comparison of the effects of sodium fluoride, inorganic phosphates, and an anabolic steroid (oxymetholone) on demineralized bone. Am. J. Dis. Child. 1969, 118, 759–764.
34. Hengge, U.R.; Stocks, K.; Faulkner, S.; Wiehler, H.; Lorenz, C.; Jentzen, W.; Hengge, D.; Ringham, G. Oxymetholone for the treatment of hiv-wasting: A double-blind, randomized, placebo-controlled phase iii trial in eugonadal men and women. HIV Clin. Trials 2003, 4, 150–163.
35. Pavlatos, A.M.; Fultz, O.; Monberg, M.J.; Vootkur, A. Review of oxymetholone: A 17α-alkylated anabolic-androgenic steroid. Clin. Ther. 2001, 23, 789–801.
36. Chesnut III, C.H.; Ivey, J.L.; Gruber, H.E.; Matthews, M.; Nelp, W.B.; Sisom, K.; Baylink, D.J. Stanozolol in postmenopausal osteoporosis: Therapeutic efficacy and possible mechanisms of action. Metabolism 1983, 32, 571–580.
37. Bork, K. Current management options for hereditary angioedema. Curr. Allergy Asthma Rep. 2012, 12, 273–280.
38. Sloane, D.E.; Lee, C.W.; Sheffer, A.L. Hereditary angioedema: Safety of long-term stanozolol therapy. J. Allergy Clin. Immunol. 2007, 120, 654–658.
39. Morton, I.K.M.; Hall, J.M. Concise Dictionary of Pharmacological Agents: Properties and Synonyms; Kluwer Academic Publishers: Dordrecht, The Netherlands, 1999.
40. Schwarz, S.; Onken, D.; Schubert, A. The steroid story of jenapharm: From the late 1940s to the early 1970s. Steroids 1999, 64, 439–445.
41. Gold, J.; Batterham, M.J.; Rekers, H.; Harms, M.K.; Geurts, T.B.P.; Helmyr, P.M.E.; Silva de Mendonça, J.; Carvalho, L.H.F.; Panos, G.; Pinchera, A.; et al. Effects of nandrolone decanoate compared with placebo or testosterone on hiv-associated wasting. HIV Med. 2006, 7, 146–155.
42. Geusens, P. Nandrolone decanoate: Pharmacological properties and therapeutic use in osteoporosis. Clin. Rheumatol. 1995, 14, 32–39.
43. Heinonen, E.; Alanko, A.; Gröhn, P.; Rissanen, P. Nandrolone decanoate added to tamoxifen in the treatment of advanced breast cancer. Breast Cancer Res. Treat. 1985, 5, 75–80.
44. Elks, J. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies; Springer: Dordrecht, The Netherlands, 2013.
45. Furuhjelm, U.; Eklund, J. Treatment of aplastic anemia with anabolic steroids and corticosteroids. Ann. Paediatr. Fenn. 1966, 12, 89–95.
46. Thomas, J.A. Drugs, Athletes, and Physical Performance; Springer: New York, NY, USA, 2012.
47. Ebadi, M. Desk Reference of Clinical Pharmacology; CRC Press: Boca Raton, FL, USA, 2008.
48. Cunliffe, W.J.; Menon, I.S. Treatment of behcet’s syndrome with phenformin and ethyloestrenol. Lancet 1969, 1, 1239–1240.
49. Nilsson, B.; Nilsson, I.M.; Hedner, U. Δ4-Ethylestrenol in recurrent deep venous thrombosis. Acta Med. Scand. 1981, 209, 45–49.
50. Fearnley, G.R.; Chakrabarti, R. Phenformin and ethyloestrenol for raynaud’s disease. Lancet 1969, 2, 1203.
51. Miller, R.L. The Encyclopedia of Addictive Drugs; Greenwood Publishing Group: Westport, CT, USA, 2002.
52. Watson, R.N.; Bradley, M.H.; Callahan, R.; Peters, B.J.; Kory, R.C. A six-month evaluation of an anabolic drug, norethandrolone, in underweight persons. i. weight gain. Am. J. Med. 1959, 26, 238–242.
53. Kroulik, W.J. Norethandrolone (nilevar) in the treatment of severely burned victims of the chicago school fire. J. Int. Coll. Surg. 1959, 32, 359–368.
54. Najean, Y.; Pecking, A.; Danvic, M.L.; The Cooperative Group for the Study of Aplastic and Refractory Anaemias Secretaries. Androgen therapy of aplastic anaemia -a prospective study of 352 cases. Scand. J. Haematol. 1979, 22, 343–356.
55. Schiffer, B.; Daxenberger, A.; Meyer, K.; Meyer, H.H. The fate of trenbolone acetate and melengestrol acetate after application as growth promoters in cattle: Environmental studies. Environ. Health Perspect. 2001, 109, 1145–1151.
56. Yarrow, J.F.; McCoy, S.C.; Borst, S.E. Tissue selectivity and potential clinical applications of trenbolone (17β-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids 2010, 75, 377–389.
57. Nieschlag, E.; Kumar, N.; Sitruk-Ware, R. 7α-methyl-19-nortestosterone (mentr): The population council’s contribution to research on male contraception and treatment of hypogonadism. Contraception 2013, 87, 288–295.
58. Attardi, B.J.; Engbring, J.A.; Gropp, D.; Hild, S.A. Development of dimethandrolone 17β-undecanoate (dmau) as an oral male hormonal contraceptive: Induction of infertility and recovery of fertility in adult male rabbits. J. Androl. 2011, 32, 530–540.
59. Friedel, A.; Geyer, H.; Kamber, M.; Laudenbach-Leschowsky, U.; Schänzer, W.; Thevis, M.; Vollmer, G.; Zierau, O.; Diel, P. 17β-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties. Toxicol. Lett. 2006, 165, 149–155.
60. Jasiurkowski, B.; Raj, J.; Wisinger, D.; Carlson, R.; Zou, L.; Nadir, A. Cholestatic jaundice and iga nephropathy induced by otc muscle building agent superdrol. Am. J. Gastroenterol. 2006, 101, 2659–2662.
61. Diel, P.; Friedel, A.; Geyer, H.; Kamber, M.; Laudenbach-Leschowsky, U.; Schänzer, W.; Thevis, M.; Vollmer, G.; Zierau, O. Characterisation of the pharmacological profile of desoxymethyltestosterone (madol), a steroid misused for doping. Toxicol. Lett. 2007, 169, 64–71.
62. Catlin, D.H.; Sekera, M.H.; Ahrens, B.D.; Starcevic, B.; Chang, Y.-C.; Hatton, C.K. Tetrahydrogestrinone: Discovery, synthesis, and detection in urine. Rapid Commun. Mass Spectrom. 2004, 18, 1245–1249.
63. Catlin, D.H.; Ahrens, B.D.; Kucherova, Y. Detection of norbolethone, an anabolic steroid never marketed, in athletes’ urine. Rapid Commun. Mass Spectrom. 2002, 16, 1273–1275.
64. Takeda, A.-N.; Pinon, G.M.; Bens, M.; Fagart, J.; Rafestin-Oblin, M.-E.; Vandewalle, A. The synthetic androgen methyltrienolone (r1881) acts as a potent antagonist of the mineralocorticoid receptor. Mol. Pharmacol. 2007, 71, 473–482.
65. Joseph, J.F.; Parr, M.K. Synthetic androgens as designer supplements. Curr. Neuropharmacol. 2015, 13, 89–100.
66. Piper, T.; Fusshöller, G.; Schänzer, W.; Lagojda, A.; Kuehne, D.; Thevis, M. Studies on the in vivo metabolism of methylstenbolone and detection of novel long term metabolites for doping control analysis. Drug Test. Anal. 2019, 11, 1644–1655.
67. Mohler, M.L.; Bohl, C.E.; Jones, A.; Coss, C.C.; Narayanan, R.; He, Y.; Dong, J.H.; Dalton, J.T.; Miller, D.D. Nonsteroidal selective androgen receptor modulators (sarms): Dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J. Med. Chem. 2009, 52, 3597–3617.
68. Meyer, L. FDA In Brief: FDA Warns against Using SARMs in Body-Building Products. Available online: (accessed on 6 February 2020).
69. Dalton, J.T.; Barnette, K.G.; Bohl, C.E.; Hancock, M.L.; Rodriguez, D.; Dodson, S.T.; Morton, R.A.; Steiner, M.S. The selective androgen receptor modulator gtx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: Results of a double-blind, placebo-controlled phase ii trial. J. Cachexia Sarcopenia Muscle 2011, 2, 153–161.
70. Dobs, A.S.; Boccia, R.V.; Croot, C.C.; Gabrail, N.Y.; Dalton, J.T.; Hancock, M.L.; Johnston, M.A.; Steiner, M.S. Effects of enobosarm on muscle wasting and physical function in patients with cancer: A double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013, 14, 335–345.
71. Srinath, R.; Dobs, A. Enobosarm (gtx-024, s-22): A potential treatment for cachexia. Future Oncol. 2014, 10, 187–194.
72. Crawford, J.; Prado, C.M.M.; Johnston, M.A.; Gralla, R.J.; Taylor, R.P.; Hancock, M.L.; Dalton, J.T. Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (power trials). Curr. Oncol. Rep. 2016, 18.
73. Narayanan, R.; Coss, C.C.; Dalton, J.T. Development of selective androgen receptor modulators (sarms). Mol. Cell. Endocrinol. 2018, 465, 134–142.
74. Basaria, S.; Collins, L.; Dillon, E.L.; Orwoll, K.; Storer, T.W.; Miciek, R.; Ulloor, J.; Zhang, A.; Eder, R.; Zientek, H.; et al. The safety, pharmacokinetics, and effects of lgd-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J. Gerontol.-Ser. Biol. Sci. Med. Sci. 2013, 68, 87–95.
75. Fragkaki, A.G.; Sakellariou, P.; Kiousi, P.; Kioukia-Fougia, N.; Tsivou, M.; Petrou, M.; Angelis, Y. Human in vivo metabolism study of lgd-4033. Drug Test. Anal. 2018, 10, 1635–1645.
76. Ostrowski, J.; Kuhns, J.E.; Lupisella, J.A.; Manfredi, M.C.; Beehler, B.C.; Krystek, S.R., Jr.; Bi, Y.; Sun, C.; Seethala, R.; Golla, R.; et al. Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: Potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 2007, 148, 4–12.
77. Mealy, N.E.; Bás, M. BMS-564929. Drugs Future 2004, 29, 1132.
78. Piu, F.; Gardell, L.R.; Son, T.; Schlienger, N.; Lund, B.W.; Schiffer, H.H.; Vanover, K.E.; Davis, R.E.; Olsson, R.; Bradley, S.R. Pharmacological characterization of ac-262536, a novel selective androgen receptor modulator. J. Steroid Biochem. Mol. Biol. 2008, 109, 129–137.
79. Van Oeveren, A.; Motamedi, M.; Mani, N.S.; Marschke, K.B.; López, F.J.; Schrader, W.T.; Negro-Vilar, A.; Zhi, L. Discovery of 6-n,n-bis(2,2,2-trifluoroethyl)amino-4- trifluoromethylquinolin-2(1h)-one as a novel selective androgen receptor modulator. J. Med. Chem. 2006, 49, 6143–6146.
80. Vajda, E.G.; López, F.J.; Rix, P.; Hill, R.; Chen, Y.; Lee, K.-J.; O’Brien, Z.; Chang, W.Y.; Meglasson, M.D.; Lee, Y.-H. Pharmacokinetics and pharmacodynamics of lgd-3303 [9-chloro-2-ethyl-1- methyl-3-(2,2,2-trifluoroethyl)-3h-pyrrolo-[3,2-f]quinolin-7(6h)-one], an orally available nonsteroidal-selective androgen receptor modulator. J. Pharmacol. Exp. Ther. 2009, 328, 663–670.
81. Hanada, K.; Furuya, K.; Yamamoto, N.; Nejishima, H.; Ichikawa, K.; Nakamura, T.; Miyakawa, M.; Amano, S.; Sumita, Y.; Oguro, N. Bone anabolic effects of s-40503, a novel nonsteroidal selective androgen receptor modulator (sarm), in rat models of osteoporosis. Biol. Pharm. Bull. 2003, 26, 1563–1569.
82. Jones, A.; Chen, J.; Hwang, D.J.; Miller, D.D.; Dalton, J.T. Preclinical characterization of a (s)-n-(4-cyano-3-trifluoromethyl-phenyl)- 3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: A selective androgen receptor modulator for hormonal male contraception. Endocrinology 2009, 150, 385–395.
83. Hansson, A.; Knych, H.; Stanley, S.; Thevis, M.; Bondesson, U.; Hedeland, M. Investigation of the selective androgen receptor modulators s1, s4 and s22 and their metabolites in equine plasma using high-resolution mass spectrometry. Rapid Commun. Mass Spectrom. 2016, 30, 833–842.
84. Chen, J.; Dong, J.H.; Bohl, C.E.; Miller, D.D.; Dalton, J.T. A selective androgen receptor modulator for hormonal male contraception. J. Pharmacol. Exp. Ther. 2005, 312, 546–553.
85. Miller, C.P.; Shomali, M.; Lyttle, C.R.; O’dea, L.S.L.; Herendeen, H.; Gallacher, K.; Paquin, D.; Compton, D.R.; Sahoo, B.; Kerrigan, S.A.; et al. Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (sarm) rad140. ACS Med. Chem. Lett. 2011, 2, 124–129.
86. Gao, W.; Dalton, J.T. Expanding the therapeutic use of androgens via selective androgen receptor modulators (sarms). Drug Discov. Today 2007, 12, 241–248.
87. Yin, D.; Xu, H.; He, Y.; Kirkovsky, L.I.; Miller, D.D.; Dalton, J.T. Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. J. Pharmacol. Exp. Ther. 2003, 304, 1323–1333.
88. Thevis, M. Detection of the arylpropionamide-derived selective androgen receptor modulator (sarm) s-4 (andarine) in a black-market product. Drug Test. Anal. 2009, 1, 387–392.
89. Hamann, L.G.; Mani, N.S.; Davis, R.L.; Wang, X.-N.; Marschke, K.B.; Jones, T.K. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]- quinoline (lg121071) [3]. J. Med. Chem. 1999, 42, 210–212.
90. Schmidt, A.; Harada, S.-I.; Kimmel, D.B.; Bai, C.; Chen, F.; Rutledge, S.J.; Vogel, R.L.; Scafonas, A.; Gentile, M.A.; Nantermet, P.V.; et al. Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J. Biol. Chem. 2009, 284, 36367–36376.
91. Schmidt, A.; Kimmel, D.B.; Bai, C.; Scafonas, A.; Rutledge, S.; Vogel, R.L.; McElwee-Witmer, S.; Chen, F.; Nantermet, P.V.; Kasparcova, V.; et al. Discovery of the selective androgen receptor modulator mk-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J. Biol. Chem. 2010, 285, 17054–17064.
92. Gao, W.; Kim, J.; Dalton, J.T. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm. Res. 2006, 23, 1641–1658.
93. Yatsu, T.; Kusakabe, T.; Kato, K.; Inouye, Y.; Nemoto, K.; Kanno, Y. Selective androgen receptor modulator, yk11, up-regulates osteoblastic proliferation and differentiation in mc3t3-e1 cells. Biol. Pharm. Bull. 2018, 41, 394–398.
94. Brown, G.A.; Vukovich, M.; King, D.S. Testosterone prohormone supplements. Med. Sci. Sports Exerc. 2006, 38, 1451–1460.
95. Yen, S.S.C. Dehydroepiandrosterone sulfate and longevity: New clues for an old friend. Proc. Natl. Acad. Sci. USA 2001, 98, 8167–8169.
96. Van Gammeren, D.; Falk, D.; Antonio, J. Effects of norandrostenedione and norandrostenediol in resistance-trained men. Nutrition 2002, 18, 734–737.
97. Warren, M.P.; Constantini, N.W. Sports Endocrinology; Humana Press: Totowa, NJ, USA, 2000.
98. Pokrywka, A.; Obmiński, Z.; Malczewska-Lenczowska, J.; Fijałek, Z.; Turek-Lepa, E.; Grucza, R. Insights into supplements with tribulus terrestris used by athletes. J. Hum. Kinet. 2014, 41, 99–105.
99. Sautour, M.; Mitaine-Offer, A.-C.; Lacaille-Dubois, M.-A. The dioscorea genus: A review of bioactive steroid saponins. J. Nat. Med. 2007, 61, 91–101.
100. Price, E.J.; Wilkin, P.; Sarasan, V.; Fraser, P.D. Metabolite profiling of dioscorea (yam) species reveals underutilised biodiversity and renewable sources for high-value compounds. Sci. Rep. 2016, 6.
101. Yi, D.; Yan-Yong, C.; De-Zu, W.; Chong-Ren, Y. Steroidal saponins from a cultivated form of agave sisalana. Phytochemistry 1989, 28, 2787–2791.
102. Parr, M.K.; Ambrosio, G.; Wuest, B.; Mazzarino, M.; de la Torre, X.; Sibilia, F.; Joseph, J.F.; Diel, P.; Botrè, F. Targeting the administration of ecdysterone in doping control samples. Forensic Toxicol. 2020, 38, 172–184.
103. Koduru, S.; Kumar, R.; Srinivasan, S.; Evers, M.B.; Damodaran, C. Notch-1 inhibition by withaferin-a: A therapeutic target against colon carcinogenesis. Mol. Cancer Ther. 2010, 9, 202–210.
104. Davydov, M.; Krikorian, A.D. Eleutherococcus senticosus (rupr. and maxim.) maxim. (araliaceae) as an adaptogen: A closer look. J. Ethnopharmacol. 2000, 72, 345–393.
105. Park, J.D.; Rhee, D.K.; Lee, Y.H. Biological activities and chemistry of saponins from panax ginseng c. a. meyer. Phytochem. Rev. 2005, 4, 159–175.
106. Shaw, I.C. Food Supplements. In Food Safety: The Science of Keeping Food Safe; Wiley-Blackwell: Chichester, UK, 2018; pp. 452–483.
107. Miyake, K.; Tezuka, Y.; Awale, S.; Li, F.; Kadota, S. Quassinoids from eurycoma longifolia. J. Nat. Prod. 2009, 72, 2135–2140.
108. Szewczyk, K.; Zidorn, C. Ethnobotany, phytochemistry, and bioactivity of the genus turnera (passifloraceae) with a focus on damiana-turnera diffusa. J. Ethnopharmacol. 2014, 152, 424–443.
109. Abarikwu, S.O.; Onuah, C.L.; Singh, S.K. Plants in the management of male infertility. Andrologia 2020, 52.
110. Neumann, F. The antiandrogen cyproterone acetate: Discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp. Clin. Endocrinol. Diabetes 1994, 102, 1–32.
111. Diviccaro, S.; Melcangi, R.C.; Giatti, S. Post-finasteride syndrome: An emerging clinical problem. Neurobiol. Stress 2020, 12, 100209.
112. De Bono, J.S.; Logothetis, C.J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chi, K.N.; Jones, R.J.; Goodman, O.B., Jr.; Saad, F.; et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 2011, 364, 1995–2005.
113. Bromham, D.R.; Booker, M.W.; Rose, G.L.; Wardle, P.G.; Newton, J.R. A multicentre comparative study of gestrinone and danazol in the treatment of endometriosis. J. Obstet. Gynaecol. 1995, 15, 188–194.